Shares of Adaptive Biotechnologies Corp (ADPT) jumped 5.03% in Thursday's pre-market trading session after the company reported better-than-expected full year 2024 earnings results. The biotech firm's earnings per share surpassed analyst estimates by 3.2%, despite posting a net loss for the year.
ADPT's full year 2024 revenue grew 5.1% year-over-year to $179 million, in line with estimates. While the company remained unprofitable with a net loss of $159.5 million, the loss narrowed by 29% compared to the previous year, indicating improving financial performance.
Looking ahead, analysts forecast ADPT's revenue to grow at an impressive 18% annualized rate over the next three years, outpacing the 6% growth projected for the broader life sciences industry. However, the company still faces some risks, with two warning signs identified by analysts.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。